World Patient Safety Summit Aims to Reduce Unnecessary C-Sections
Two survivors of C-section delivery and postpartum complications will be part of a distinguished panel at the upcoming 2018 World Patient Safety Science & Technology Summit in London, on Saturday, February 24.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180213006342/en/
Kristen Terlizzi will share her near-fatal experience of postpartum care at the 6th Annual World Patient Safety, Science & Technology Summit in London, UK. (Photo: Business Wire)
According to researchers, C-sections or deliveries of newborns by caesarean section, is on the rise but nearly half of those cases are unnecessary and complications from the procedure are not well known or understood. The Patient Safety Movement Foundation is pleased to announce the panelists participating in the upcoming Reducing Unnecessary C-Sections in Hospitals Panel. These include Jill Arnold and Kristen Terlizzi who have become fierce patient advocates since their near fatal experiences in delivering their infants by C-section and the complications that followed.
The Statistics: Internationally, C-sections are on the rise ranging from an average of 40.5% in Latin America/Caribbean area to 7.3% in Africa (Betran 2016). In the United States, one-third of patients give birth surgically (Martin, 2017) and international experts have identified this high cesarean rate as a significant maternal health safety issue (Council on Patient Safety in Women’s Health Care 2016).
Kristen Terlizzi’s post-partum medical care was so extreme, it inspired a scientific journal case study. An earlier C-section left her with a condition called Placenta Accreta – where placental tissue remains and spreads affecting other organs. Hemorrhaging during corrective surgery was so acute, she had her entire blood supply replaced.
Jill Arnold was the picture of health and breezed through a low-risk pregnancy and delivery but the lack of emphasis on postpartum care in the U.S. left her at risk. She began showing symptoms of DVT – Deep Vein Thrombosis – which could have easily killed her. “A leg-length clot had developed in a superficial vein that extended from my ankle all the way up to the groin,” said Arnold.
Unnecessary C-sections also pose long-term health risks including subsequent uterine scar rupture, abnormal placentation, increased risk of hemorrhage, and hysterectomy (Bauserman 2015, Marshall 2011, Rageth 1999, Galyean 2009) where there is an exponential increase in such complications with the number of prior cesareans (Clark 1985).
The Reducing Unnecessary C-sections panel will discuss best practices from around the world and announce the new Actionable Patient Safety Solutions related to this topic.
Members of the Global Panel include:
- Moderator: David C. Lagrew Jr., MD, Executive Medical Director of Women’s Service, St. Joseph-Hoag Health Region of Providence Healthcare – Dr. Lagrew is a maternal fetal medicine specialist and physician informaticist with a special interest in maternal quality improvement. He has helped develop and pioneer techniques in cesarean section reduction, emergent cesarean section drills, and maternal quality improvement in techniques.
- Kristen Terlizzi, Co-founder, National Accreta Foundation – Ms. Terlizzi now shares her patient story to educate audiences on abnormal placentation and the downstream costs of cesarean deliveries. Her medical case report is published in the official journal of the American Congress of Obstetricians and Gynecologists (ACOG) and her patient story has been featured in Vox Media, the Wall Street Journal and People.com.
- Jill Arnold, Co-founder, National Accreta Foundation - Jill Arnold’s research on C-section, VBAC and other delivery method data led to the creation of a registry of national hospital-level data that Consumer Reports licensed in 2013. Jill currently serves as the Vice Chair of the Arkansas Healthcare Transparency Initiative Task Force Board, is an Editorial Board Member of the Institute for Perinatal Quality Improvement and an Expert Consultant to the Delivery Decisions Initiative at Harvard’s Ariadne Labs as well as serving as a member of the steering committee of the California Maternal Quality Care Collaborative (CMQCC) Maternal Data Center since 2013.
- Siddarth Satish, Founder, Chief Executive Officer, Gauss Surgical - Siddarth Satish is the Founder and CEO of Gauss Surgical, a medical technology company using computer vision and machine learning to make surgery and childbirth safer and more cost-effective. He serves on the Technology Committee of the Anesthesia Patient Safety Foundation, and was named to the Forbes 30 Under 30 list in healthcare.
- Robert M. Silver, MD, Professor of Obstetrics and Gynecology, University of Utah Health Sciences Center – Dr. Silver joined the University of Utah Maternal-Fetal Medicine Division after completing his fellowship there in 1994. He is serving as the Chief of the Division of Maternal-Fetal Medicine and as Co-Director of Labor and Delivery at the UUHSC.
For more information, please visit the Patient Safety Movement Foundation website. Members of the media may request a press pass by visiting http://bit.ly/2mCeyay or by contacting Tanya Lyon – phone (949) 351-2858 or email email@example.com.
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, (949) 351-2858
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme